Herlitz J, Elmfeldt D, Holmberg S, Málek I, Nyberg G, Pennert K, Rydén L, Swedberg K, Vedin A, Waagstein F
Am J Cardiol. 1984 Jun 25;53(13):9D-14D.
During the 3-month blind treatment period there were 40 deaths in the metoprolol group compared with 62 deaths in the placebo group (p = 0.024). During the first year (after 3 months the 2 groups were treated similarly) there were 64 deaths in the metoprolol group vs 93 in the placebo group (p = 0.017) and during 2 years 92 patients died in the metoprolol group vs 120 in the placebo group (p = 0.043). The relative incidence of different causes of death did not differ significantly between the 2 treatment groups, indicating that metoprolol reduced all causes of death to the same extent as its effect on overall mortality.
在为期3个月的盲法治疗期内，美托洛尔组有40例死亡，而安慰剂组有62例死亡（p = 0.024）。在第一年（3个月后两组接受相似治疗），美托洛尔组有64例死亡，安慰剂组有93例死亡（p = 0.017）；在两年期间，美托洛尔组有92例患者死亡，安慰剂组有120例死亡（p = 0.043）。两个治疗组之间不同死因的相对发生率无显著差异，这表明美托洛尔降低所有死因的程度与其对总死亡率的影响程度相同。
